Gary Deed

[The Lancet Diabetes & Endocrinology @TheLancetEndo]

In the past 5 years alone, the number of clinical trials studying #obesity medications has increased nearly five-fold and more than 150 potential drugs are currently in the development pipeline https://t.co/IFPyEU8bKn
#weightloss #GLP-1 receptor agonists

[Eric Topol @EricTopol]

Very good review on this topic, by @DanielJDrucker @NatureCancer
https://t.co/wOZiT7VL7l

[Diabetes Care, an ADA research journal 🌟 @DiabetesCareADA]

Indirect comparison of SURPASS-CVOT and REWIND suggests tirzepatide reduces MACE-3, CV death or HF events, and all-cause mortality versus imputed placebo in #T2D with ASCVD. #DCare #Article

Read here ➡️ https://t.co/pg6NUygR3B

@AmDiabetesAssn @ADA_DiabetesPro @ADA_Pubs

[Prof Kamlesh Khunti @kamleshkhunti]

SGLT2 inhibitors - meta-analysis 18 RCTs

🫀 Reduce CV mortality
🩺 Improve kidney outcomes
📉 Lower overall mortality risk

Benefits seen in diabetes, heart failure & CKD — with signals of added survival benefit across age groups.

A true cornerstone of cardiorenal protection.

https://t.co/S4O3LYgJEf

sglt218

[Medscape @Medscape]

GLP-1 overdoses have been skyrocketing, with poison centers seeing a nearly 1500% increase in calls related to overdose or side effects of injectable weight-loss drugs since 2019, according to US National Poison Data Center.

Experts suggest that the use of compounded drugs has exacerbated the overdose problem. However, increased utilization of GLP-1s and lack of patient education are also among the contributing factors. https://t.co/wrZdbxvSKP

[Medscape @Medscape]

Gabapentinoids like gabapentin and pregabalin are associated with an increased risk for poisoning, with the highest risk occurring around treatment initiation and when combined with benzodiazepines or opioids.

In a large UK study of nearly 17,000 primary care patients, those who had co-initiation of gabapentinoids and benzodiazepines showed double the risk for hospitalization due to drug poisoning within the first month, whereas those with concomitant opioid use showed a 30% increased risk compared with those who took neither medication. https://t.co/djHDrx5vjQ

[Scott Isaacs @scottisaacsmd]

New review by Maria Gonzalez-Rellan & Daniel Drucker focuses on the expanding benefits of GLP-1 meds like semaglutide & tirzepatide. Beyond glucose/weight control: ↓ CVD events, CKD progression, MASLD, OA, sleep apnea (via anti-inflammatory paths) partly weight-loss independent.
https://t.co/hRvaPYBr1X

[Prof Kamlesh Khunti @kamleshkhunti]

Our review published

Fixed‑Dose Combination Therapy as a Strategy to Improve Antidiabetic Medication Adherence in People with Type 2 Diabetes

Unfortunately not used much in UK despite their advantages.

led by Patrick Highton

https://t.co/sJfQOp4ztO

[Medscape @Medscape]

Experts share a practical curriculum on how a proactive approach to obesity and metabolic risk can redefine long‑term liver health—identifying early warning signs and enabling timely intervention.

Explore this CME ▶️ https://t.co/ilRTPnnQKD

[NEJM @NEJM]

Findings from an analysis of deidentified electronic health record data from a national database indicate that the prevalence of youth-onset type 2 diabetes has increased substantially during the past decade. Full study results: https://t.co/8H7RiG7PDW

[NEJM @NEJM]

A new review by Clifford J. Rosen, MD, and Julie R. Ingelfinger, MD, describes a new generation of treatment with GLP-1 receptor agonists for persons with obesity with or without diabetes or prediabetes. Learn more: https://t.co/SNdSrVXqWJ

[Prof Kamlesh Khunti @kamleshkhunti]

Systematic review

GLP-1RA cessation is associated with a predictable and decelerating pattern of weight regain

Plateau below pre-treatment levels, suggesting that partial weight-loss benefit may persist long-term but is substantially attenuated.

https://t.co/0M89a0YC9M

[Gary Deed @garydeed]

Health Minister Hon Mark Butler #markbutler
Speaking at the #NationalDiabetesSummit
Working with community to improve Australian Diabetes management

[Gary Deed @garydeed]

National Diabetes Summit

Powerful voices leading changes in the diabetes landscape

[JAMA @JAMA_current]

Among patients with #diabetes but without known significant atherosclerosis, intensive LDL-C lowering with evolocumab plus statin reduced risk of first major cardiovascular event vs placebo in the VESALIUS-CV trial.

#ACC26 @ACCinTouch

🎥 Watch the video and read the full article:
https://t.co/CfJPEqn8mO

[Michael Mindrum, MD @MichaelMindrum]

What happens when a patient on semaglutide progresses to dialysis — do you stop it?

📢New pooled RCT analysis (SUSTAIN-6, SELECT, FLOW, SOUL; n=34,064) finally addresses this clinical gap.

📈307 patients initiated dialysis
🟢165 stayed on treatment
🔴SAEs: 45% (sema) vs 57% (placebo)
🫀MACE rate: 9.7 vs 16.1 per 100 PY
☠️All-cause mortality: 13.8 vs 18.1 per 100 PY
✅ Numerically favourable across the board.

Continuation appears safe — not powered for efficacy, but reassuring for a question we face regularly.

🏁A dedicated trial is still needed.

https://t.co/IYvbiuxXx9

[Samuel Hume @DrSamuelBHume]

At the start of this year I wrote about the 5 most important clinical trials to watch

1. RAS inhibition in pancreatic cancer
2. Targeting inflammation to cut cardiovascular risk
3. Targeting lipoprotein(a) to cut cardiovascular risk
4. Tirzepatide vs. Retatrutide in obesity
5. A next-generation amyloid antibody

Read it here! https://t.co/b0vanZ232G

[Daniel J Drucker @DanielJDrucker]

As the weight loss-independent actions of GLP-1 medicines unfold a greater reduction in PsA disease activity (ACR50) was seen as early as Week 4 in the Ixekizumab and Tirzepatide treatment arm before clinically meaningful weight loss was observed https://t.co/8VmSjdw3Fv

[Medscape @Medscape]

An analysis of prescribing decisions for nearly 30,000 patients found most clinicians did not order preventive medications for patients with elevated lipoprotein(a) (Lp[a]) levels who were at low risk for atherosclerotic cardiovascular disease (ASCVD).

However, some clinicians did prescribe lipid-lowering therapy. In rare cases, patients received aspirin or a PCSK9 inhibitor, according to a multicenter retrospective cohort study of patients who were tested for Lp(a). https://t.co/0nBaAXhuLx

[Ethan J. Weiss @ethanjweiss]

Another win for the lower is better crowd…

Intensive LDL Cholesterol Targeting in Atherosclerotic Cardiovascular Disease | New England Journal of Medicine https://t.co/z8WqTaeLSJ